{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:02:50Z","timestamp":1772269370477,"version":"3.50.1"},"reference-count":184,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Regional Operational Program Center 2020, Competitiveness Factors Operational Program","award":["COMPETE 2020"],"award-info":[{"award-number":["COMPETE 2020"]}]},{"name":"National Funds through Foundation for Science and Technology (FCT): BrainHealth2020","award":["CENTRO-01-0145-FEDER-000008"],"award-info":[{"award-number":["CENTRO-01-0145-FEDER-000008"]}]},{"name":"ViraVector","award":["CENTRO-01-0145-FEDER-022095"],"award-info":[{"award-number":["CENTRO-01-0145-FEDER-022095"]}]},{"name":"CortaCAGs","award":["POCI-01-0145-FEDER-016719"],"award-info":[{"award-number":["POCI-01-0145-FEDER-016719"]}]},{"name":"SpreadSilencing","award":["POCI-01-0145-FEDER-029716"],"award-info":[{"award-number":["POCI-01-0145-FEDER-029716"]}]},{"name":"Imagene","award":["POCI-01-0145-FEDER-016807"],"award-info":[{"award-number":["POCI-01-0145-FEDER-016807"]}]},{"name":"CancelStem","award":["POCI-01-0145-FEDER-016390"],"award-info":[{"award-number":["POCI-01-0145-FEDER-016390"]}]},{"name":"CancelStem","award":["PD\/BD\/114171\/2016"],"award-info":[{"award-number":["PD\/BD\/114171\/2016"]}]},{"name":"CancelStem","award":["SFRH\/BD\/51673\/2011"],"award-info":[{"award-number":["SFRH\/BD\/51673\/2011"]}]},{"name":"CancelStem","award":["SFRH\/BPD\/87552\/2012"],"award-info":[{"award-number":["SFRH\/BPD\/87552\/2012"]}]},{"name":"CancelStem","award":["PTDC\/MED-NEU\/32309\/2017"],"award-info":[{"award-number":["PTDC\/MED-NEU\/32309\/2017"]}]},{"name":"Association Fran\u00e7aise contre les Myopathies -T\u00e9l\u00e9thon","award":["21163"],"award-info":[{"award-number":["21163"]}]},{"name":"European Union H2020","award":["643417"],"award-info":[{"award-number":["643417"]}]},{"DOI":"10.13039\/100002243","name":"National Ataxia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002243","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Portuguese Biomedical Research Fund"},{"name":"Richard Chin and Lily Lock Machado-Joseph Disease Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polyglutamine (polyQ) disorders are a group of nine neurodegenerative diseases that share a common genetic cause, which is an expansion of CAG repeats in the coding region of the causative genes that are otherwise unrelated. The trinucleotide expansion encodes for an expanded polyQ tract in the respective proteins, resulting in toxic gain-of-function and eventually in neurodegeneration. Currently, no disease-modifying therapies are available for this group of disorders. Nevertheless, given their monogenic nature, polyQ disorders are ideal candidates for therapies that target specifically the gene transcripts. Antisense oligonucleotides (ASOs) have been under intense investigation over recent years as gene silencing tools. ASOs are small synthetic single-stranded chains of nucleic acids that target specific RNA transcripts through several mechanisms. ASOs can reduce the levels of mutant proteins by breaking down the targeted transcript, inhibit mRNA translation or alter the maturation of the pre-mRNA via splicing correction. Over the years, chemical optimization of ASO molecules has allowed significant improvement of their pharmacological properties, which has in turn made this class of therapeutics a very promising strategy to treat a variety of neurodegenerative diseases. Indeed, preclinical and clinical strategies have been developed in recent years for some polyQ disorders using ASO therapeutics. The success of ASOs in several animal models, as well as encouraging results in the clinic for Huntington\u2019s disease, points towards a promising future regarding the application of ASO-based therapies for polyQ disorders in humans, offering new opportunities to address unmet medical needs for this class of disorders. This review aims to present a brief overview of key chemical modifications, mechanisms of action and routes of administration that have been described for ASO-based therapies. Moreover, it presents a review of the most recent and relevant preclinical and clinical trials that have tested ASO therapeutics in polyQ disorders.<\/jats:p>","DOI":"10.1093\/brain\/awz328","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T20:14:04Z","timestamp":1572898444000},"page":"407-429","source":"Crossref","is-referenced-by-count":69,"title":["Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders"],"prefix":"10.1093","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-5847","authenticated-orcid":false,"given":"Ana C","family":"Silva","sequence":"first","affiliation":[{"name":"Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal"}]},{"given":"Diana D","family":"Lobo","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal"}]},{"given":"In\u00eas M","family":"Martins","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal"},{"name":"Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal"}]},{"given":"Sara M","family":"Lopes","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal"},{"name":"Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal"}]},{"given":"Carina","family":"Henriques","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal"},{"name":"ViraVector, Viral Vector for Gene Transfer Core Facility, University of Coimbra, Coimbra, Portugal"}]},{"given":"S\u00f3nia P","family":"Duarte","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal"},{"name":"Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal"}]},{"given":"Jean-Cosme","family":"Dodart","sequence":"additional","affiliation":[{"name":"United Neuroscience, Inc., Boston, MA, USA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5816-2051","authenticated-orcid":false,"given":"Rui Jorge","family":"Nobre","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal"},{"name":"Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal"},{"name":"ViraVector, Viral Vector for Gene Transfer Core Facility, University of Coimbra, Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5831-3307","authenticated-orcid":false,"given":"Luis","family":"Pereira de Almeida","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal"},{"name":"ViraVector, Viral Vector for Gene Transfer Core Facility, University of Coimbra, Coimbra, Portugal"},{"name":"Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal"}]}],"member":"286","published-online":{"date-parts":[[2019,11,18]]},"reference":[{"key":"2020021011132661600_awz328-B1","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1073\/pnas.88.17.7595","article-title":"Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice","volume":"88","author":"Agrawal","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020021011132661600_awz328-B2","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/0024-3205(91)90480-Y","article-title":"Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera","volume":"49","author":"Akhtar","year":"1991","journal-title":"Life Sci"},{"key":"2020021011132661600_awz328-B3","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1093\/nar\/gkn115","article-title":"Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis","volume":"36","author":"Alam","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm1345","article-title":"Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology","volume":"12","author":"Alter","year":"2006","journal-title":"Nat Med"},{"key":"2020021011132661600_awz328-B5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2020021011132661600_awz328-B6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2020021011132661600_awz328-B7","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/hmg\/ddq111","article-title":"Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?","volume":"19","author":"Alves","year":"2010","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12311-018-0961-2","article-title":"Intravenously administered novel liposomes, DCL64, Deliver oligonucleotides to cerebellar Purkinje cells","volume":"18","author":"Ashizawa","year":"2019","journal-title":"Cerebellum"},{"key":"2020021011132661600_awz328-B9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/nar\/27.6.1547","article-title":"Oligonucleotide-europium complex conjugate designed to cleave the 5\u2019 cap structure of the ICAM-1 transcript potentiates antisense activity in cells","volume":"27","author":"Baker","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B10","doi-asserted-by":"crossref","first-page":"e1002481","DOI":"10.1371\/journal.pgen.1002481","article-title":"A pathogenic mechanism in Huntington\u2019s disease involves small CAG-repeated RNAs with neurotoxic activity","volume":"8","author":"Ba\u00f1ez-Coronel","year":"2012","journal-title":"PLoS Genet"},{"key":"2020021011132661600_awz328-B11","first-page":"1113","article-title":"Delivery across the blood-brain barrier of antisense directed against amyloid \u03b2: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein","volume":"297","author":"Banks","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"2020021011132661600_awz328-B12","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Prim"},{"key":"2020021011132661600_awz328-B13","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/hmg\/ddq018","article-title":"Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis","volume":"19","author":"Becanovic","year":"2010","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"2020021011132661600_awz328-B15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2020021011132661600_awz328-B16","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol Ther"},{"key":"2020021011132661600_awz328-B17","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1093\/nar\/gkf651","article-title":"Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design","volume":"30","author":"Braasch","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B18","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1016\/S0021-9258(18)47090-1","article-title":"Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding","volume":"269","author":"Brown","year":"1994","journal-title":"J Biol Chem"},{"key":"2020021011132661600_awz328-B19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s13311-018-00696-y","article-title":"Genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias","volume":"16","author":"Buijsen","year":"2019","journal-title":"Neurotherapeutics"},{"key":"2020021011132661600_awz328-B20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.neuroscience.2004.11.038","article-title":"Spinal distribution and metabolism of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats","volume":"131","author":"Butler","year":"2005","journal-title":"Neuroscience"},{"key":"2020021011132661600_awz328-B21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0165-022X(90)90084-P","article-title":"Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid","volume":"20","author":"Campbell","year":"1990","journal-title":"J Biochem Biophys Methods"},{"key":"2020021011132661600_awz328-B22","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol Ther"},{"key":"2020021011132661600_awz328-B23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/nat.2016.0642","article-title":"Distribution and penetration of intracerebroventricularly administered 2\u2032OMePS oligonucleotide in the mouse brain","volume":"27","author":"Casaca-Carreira","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"2020021011132661600_awz328-B24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.biopha.2016.09.007","article-title":"In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington\u2019s disease","volume":"84","author":"Casaca-Carreira","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"2020021011132661600_awz328-B25","doi-asserted-by":"crossref","first-page":"25185","DOI":"10.1016\/S0021-9258(17)31515-6","article-title":"Characterization and subcellular localization of ribonuclease H activities from Xenopus laevis oocytes","volume":"269","author":"Cazenave","year":"1994","journal-title":"J Biol Chem"},{"key":"2020021011132661600_awz328-B26","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1742-4658.2009.06908.x","article-title":"Ribonuclease H: the enzymes in eukaryotes","volume":"276","author":"Cerritelli","year":"2009","journal-title":"FEBS J"},{"key":"2020021011132661600_awz328-B27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/108729002761381320","article-title":"Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain","volume":"12","author":"Chauhan","year":"2002","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"2020021011132661600_awz328-B28","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"2020021011132661600_awz328-B29","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov Disord"},{"key":"2020021011132661600_awz328-B30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-319-71779-1_5","article-title":"La. X-linked spinal and bulbar muscular atrophy: from clinical genetic features and molecular pathology to mechanisms underlying disease toxicity","volume":"1049","author":"Cortes","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2020021011132661600_awz328-B31","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2020021011132661600_awz328-B32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/ard.1991.1.11","article-title":"Pathways of degradation and mechanism of action","volume":"20","author":"Dagle","year":"1991","journal-title":"Antisense Res Dev"},{"key":"2020021011132661600_awz328-B33","doi-asserted-by":"crossref","first-page":"e1005182","DOI":"10.1371\/journal.pgen.1005182","article-title":"Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model","volume":"11","author":"Dansithong","year":"2015","journal-title":"PLoS Genet"},{"key":"2020021011132661600_awz328-B34","doi-asserted-by":"crossref","first-page":"e0171127","DOI":"10.1371\/journal.pone.0171127","article-title":"The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain","volume":"12","author":"Datson","year":"2017","journal-title":"PLoS One"},{"key":"2020021011132661600_awz328-B35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/hmg\/7.2.165","article-title":"Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7)","volume":"7","author":"David","year":"1998","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B36","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/0006-2952(94)90171-6","article-title":"Stability of peptide nucleic acids in human serum and cellular extracts","volume":"48","author":"Demidov","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"2020021011132661600_awz328-B37","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s13311-013-0194-5","article-title":"Antisense oligonucleotides: treating neurodegeneration at the level of RNA","volume":"10","author":"DeVos","year":"2013","journal-title":"Neurotherapeutics"},{"key":"2020021011132661600_awz328-B38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.omtn.2017.11.004","article-title":"A sensitive in vitro approach to assess the hybridization-dependent toxic potential of high affinity gapmer oligonucleotides","volume":"10","author":"Dieckmann","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"2020021011132661600_awz328-B39","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice","volume":"26","author":"Dragatsis","year":"2000","journal-title":"Nat Genet"},{"key":"2020021011132661600_awz328-B40","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/hmg\/ddr217","article-title":"Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum","volume":"20","author":"Du","year":"2011","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/ard.1991.1.141","article-title":"Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3\u2032 exonuclease in plasma","volume":"1","author":"Eder","year":"1991","journal-title":"Antisense Res Dev"},{"key":"2020021011132661600_awz328-B42","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/365566a0","article-title":"PNA hybridizes to complementary oligonucleotides obeying the Watson\u2013Crick hydrogen-bonding rules","volume":"365","author":"Egholm","year":"1993","journal-title":"Nature"},{"key":"2020021011132661600_awz328-B43","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature09320","article-title":"Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS","volume":"466","author":"Elden","year":"2010","journal-title":"Nature"},{"key":"2020021011132661600_awz328-B44","doi-asserted-by":"crossref","first-page":"e24308","DOI":"10.1371\/journal.pone.0024308","article-title":"Targeting several CAG expansion diseases by a single antisense oligonucleotide","volume":"6","author":"Evers","year":"2011","journal-title":"PLoS One"},{"key":"2020021011132661600_awz328-B45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/nat.2013.0452","article-title":"Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification","volume":"24","author":"Evers","year":"2014","journal-title":"Nucleic Acid Ther"},{"key":"2020021011132661600_awz328-B46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nbd.2013.04.019","article-title":"Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon","volume":"58","author":"Evers","year":"2013","journal-title":"Neurobiol Dis"},{"key":"2020021011132661600_awz328-B47","first-page":"1005","article-title":"Central and peripheral administration of antisense oligonucleotide targeting amyloid precursor protein improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (APPswe) Mice. J Alzheimer\u2019s","volume":"40","author":"Farr","year":"2014","journal-title":"Dis"},{"key":"2020021011132661600_awz328-B48","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1093\/nar\/25.22.4429","article-title":"The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes","volume":"25","author":"Freier","year":"1997","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B49","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1081\/NCN-120022731","article-title":"Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras","volume":"22","author":"Frieden","year":"2003","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2020021011132661600_awz328-B50","doi-asserted-by":"crossref","first-page":"e123193","DOI":"10.1172\/jci.insight.123193","article-title":"Antisense oligonucleotide\u2013mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles","volume":"3","author":"Friedrich","year":"2018","journal-title":"JCI Insight"},{"key":"2020021011132661600_awz328-B51","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1021\/ja00970a054","article-title":"Nucleoside phosphorothioatezs","volume":"88","author":"Fritz","year":"1966","journal-title":"J Am Chem Soc"},{"key":"2020021011132661600_awz328-B52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"2020021011132661600_awz328-B53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.bcp.2009.04.013","article-title":"Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2\u2032-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN","volume":"78","author":"Geary","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"2020021011132661600_awz328-B54","first-page":"890","article-title":"Pharmacokinetic properties of 2\u2032-O-(2-Methoxyethyl)-modified oligonucleotide analogs in rats","volume":"296","author":"Geary","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"2020021011132661600_awz328-B55","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","article-title":"Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin","volume":"125","author":"Graham","year":"2006","journal-title":"Cell"},{"key":"2020021011132661600_awz328-B56","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1021\/ja00086a062","article-title":"Oligodeoxyribonucleotide N3\u2032\u2192P5\u2032 phosphoramidates: synthesis and hybridization properties","volume":"116","author":"Gryaznov","year":"1994","journal-title":"J Am Chem Soc"},{"key":"2020021011132661600_awz328-B57","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/nar\/24.8.1508","article-title":"Oligonucleotide N3\u2019\u2013&gt;P5\u2019 phosphoramidates as antisense agents","volume":"24","author":"Gryaznov","year":"1996","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B58","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.imbio.2009.09.003","article-title":"Alternating 2\u2032-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist","volume":"215","author":"Hamm","year":"2010","journal-title":"Immunobiology"},{"key":"2020021011132661600_awz328-B59","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"2020021011132661600_awz328-B60","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/hmg\/dds427","article-title":"Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2","volume":"22","author":"Hansen","year":"2013","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1215\/15228517-2007-052","article-title":"New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163","volume":"10","author":"Hashizume","year":"2008","journal-title":"Neurol Oncol"},{"key":"2020021011132661600_awz328-B62","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B63","first-page":"468","article-title":"Chemically modified oligonucleotides exhibit decreased immune stimulation in mice","volume":"292","author":"Henry","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2020021011132661600_awz328-B64","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Inhibiting expression of mutant huntingtin and ataxin-3 by targeting expanded CAG repeat RNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat Biotechnol"},{"key":"2020021011132661600_awz328-B65","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"2020021011132661600_awz328-B66","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am J Hum Genet"},{"key":"2020021011132661600_awz328-B67","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","article-title":"Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation","volume":"6","author":"Hudziak","year":"1996","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"2020021011132661600_awz328-B68","doi-asserted-by":"crossref","first-page":"e6235","DOI":"10.1371\/journal.pone.0006235","article-title":"Dissociated fear and spatial learning in mice with deficiency of ataxin-2","volume":"4","author":"Huynh","year":"2009","journal-title":"PLoS One"},{"key":"2020021011132661600_awz328-B69","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2020021011132661600_awz328-B70","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neulet.2015.05.007","article-title":"Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression","volume":"598","author":"Jan","year":"2015","journal-title":"Neurosci Lett"},{"key":"2020021011132661600_awz328-B71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/nar\/24.5.829","article-title":"NMR investigations of duplex stability of phosphorothioate and phosphorodithioate DNA analogues modified in both strands","volume":"24","author":"Jaroszewski","year":"1996","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B72","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/mt.2008.120","article-title":"Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice","volume":"16","author":"Jearawiriyapaisarn","year":"2008","journal-title":"Mol Ther"},{"key":"2020021011132661600_awz328-B73","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1093\/nar\/22.22.4591","article-title":"Target-specific arrest of mRNA translation by antisense 2\u2032-O- alkyloligoribonucleotides","volume":"22","author":"Johansson","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B74","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B75","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addr.2015.04.005","article-title":"Cellular uptake and intracellular trafficking of oligonucleotides","volume":"87","author":"Juliano","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"2020021011132661600_awz328-B76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pharmthera.2011.10.002","article-title":"MicroRNAs in neurodegenerative diseases and their therapeutic potential","volume":"133","author":"Junn","year":"2012","journal-title":"Pharmacol Ther"},{"key":"2020021011132661600_awz328-B77","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-319-71779-1_9","article-title":"Molecular mechanisms and therapeutic strategies in spinocerebellar staxia type 7","volume":"1049","author":"Karam","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2020021011132661600_awz328-B78","doi-asserted-by":"crossref","first-page":"30377","DOI":"10.1038\/srep30377","article-title":"Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides","volume":"6","author":"Kasuya","year":"2016","journal-title":"Sci Rep"},{"key":"2020021011132661600_awz328-B79","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1523\/JNEUROSCI.3032-06.2006","article-title":"Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration","volume":"26","author":"Katsuno","year":"2006","journal-title":"J Neurosci"},{"key":"2020021011132661600_awz328-B80","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng1194-221","article-title":"CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1","volume":"8","author":"Kawaguchi","year":"1994","journal-title":"Nat Genet"},{"key":"2020021011132661600_awz328-B81","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2013.279","article-title":"Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy","volume":"22","author":"Keiser","year":"2014","journal-title":"Mol Ther"},{"key":"2020021011132661600_awz328-B82","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1093\/hmg\/ddr380","article-title":"Impaired motoneuronal retrograde transport in two models of SBMA implicates two sites of androgen action","volume":"20","author":"Kemp","year":"2011","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B83","doi-asserted-by":"crossref","first-page":"12932","DOI":"10.1093\/nar\/gkx1073","article-title":"RNase H sequence preferences influence antisense oligonucleotide efficiency","volume":"45","author":"Kie\u0142pi\u0144ski","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B84","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1093\/nar\/gkr089","article-title":"Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes","volume":"39","author":"Koller","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B85","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"2020021011132661600_awz328-B86","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.omtn.2019.07.004","article-title":"Suppression of mutant protein expression in SCA3 and SCA1 mice using a CAG repeat-targeting antisense oligonucleotide","volume":"17","author":"Kourkouta","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"2020021011132661600_awz328-B87","first-page":"340","article-title":"An aquaporin 4 antisense oligonucleotide loaded, brain targeted nanoparticulate system design","volume":"69","author":"Kozlu","year":"2014","journal-title":"Pharmazie"},{"key":"2020021011132661600_awz328-B88","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/ncomms2514","article-title":"Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex","volume":"4","author":"Krau\u00df","year":"2013","journal-title":"Nat Commun"},{"key":"2020021011132661600_awz328-B89","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","article-title":"Antisense technologies: improvement through novel chemical modifications","volume":"270","author":"Kurreck","year":"2003","journal-title":"Eur J Biochem"},{"key":"2020021011132661600_awz328-B90","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1074\/jbc.M109.075028","article-title":"Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease","volume":"285","author":"Landles","year":"2010","journal-title":"J Biol Chem"},{"key":"2020021011132661600_awz328-B91","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrg2748","article-title":"Repeat expansion disease: progress and puzzles in disease pathogenesis","volume":"11","author":"La Spada","year":"2010","journal-title":"Nat Rev Genet"},{"key":"2020021011132661600_awz328-B92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/352077a0","article-title":"Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy","volume":"352","author":"La Spada","year":"1991","journal-title":"Nature"},{"key":"2020021011132661600_awz328-B93","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/ncomms3753","article-title":"Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress","volume":"4","author":"Leitman","year":"2013","journal-title":"Nat Commun"},{"key":"2020021011132661600_awz328-B94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0167-4781(99)00140-2","article-title":"review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides","volume":"1489","author":"Levin","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"2020021011132661600_awz328-B183","doi-asserted-by":"crossref","first-page":"7819","DOI":"10.1093\/nar\/gku484","article-title":"TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells","volume":"42","author":"Liang","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B184","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1093\/nar\/gkw144","article-title":"Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2\u2032-modifications and enhances antisense activity","volume":"44","author":"Liang","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B95","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"2020021011132661600_awz328-B96","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/nar\/gkv143","article-title":"Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages","volume":"43","author":"Liang","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B97","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/hmg\/11.17.1967","article-title":"Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor","volume":"11","author":"Lieberman","year":"2002","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","article-title":"Polyglutamine repeats in neurodegenerative diseases","volume":"14","author":"Lieberman","year":"2019","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"2020021011132661600_awz328-B99","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.celrep.2014.02.008","article-title":"Peripheral Androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy","volume":"7","author":"Lieberman","year":"2014","journal-title":"Cell Rep"},{"key":"2020021011132661600_awz328-B100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-3956(98)80047-2","article-title":"Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain","volume":"33","author":"Liebsch","year":"1999","journal-title":"J Psychiatr Res"},{"key":"2020021011132661600_awz328-B101","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/mol.106.025015","article-title":"Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate","volume":"71","author":"Lima","year":"2007","journal-title":"Mol Pharmacol"},{"key":"2020021011132661600_awz328-B102","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/1074-5521(94)90039-6","article-title":"Stabilizing effects of the RNA 2\u2032-substituent: crystal structure of an oligodeoxynucleotide duplex containing 2\u2032-O-methylated adinosines","volume":"1","author":"Lubinil","year":"1994","journal-title":"Chem Biol"},{"key":"2020021011132661600_awz328-B103","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1097-2765(02)00602-0","article-title":"Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions","volume":"10","author":"Lunkes","year":"2002","journal-title":"Mol Cell"},{"key":"2020021011132661600_awz328-B104","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1523\/JNEUROSCI.18-14-05508.1998","article-title":"Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation","volume":"18","author":"Matilla","year":"1998","journal-title":"J Neurosci"},{"key":"2020021011132661600_awz328-B105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-3-319-71779-1_20","article-title":"Gene therapies for polyglutamine diseases","volume":"1049","author":"Matos","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2020021011132661600_awz328-B106","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pneurobio.2011.06.007","article-title":"Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease","volume":"95","author":"Matos","year":"2011","journal-title":"Prog Neurobiol"},{"key":"2020021011132661600_awz328-B107","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol Ther"},{"key":"2020021011132661600_awz328-B108","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1074\/jbc.274.3.1715","article-title":"Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression","volume":"274","author":"Mckay","year":"1999","journal-title":"J Biol Chem"},{"key":"2020021011132661600_awz328-B109","first-page":"1","article-title":"Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice","author":"McLoughlin","year":"2018","journal-title":"Ann Neurol"},{"key":"2020021011132661600_awz328-B110","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/nar\/gkw112","article-title":"Stabilin-1 and stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver","volume":"44","author":"Miller","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B111","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol"},{"key":"2020021011132661600_awz328-B112","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1093\/nar\/gkq534","article-title":"Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor","volume":"38","author":"Ming","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B113","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","article-title":"Evaluation of 2\u2032-modified oligonucleotides containing 2\u2032-deoxy gaps as antisense inhibitors of gene expression","volume":"268","author":"Monia","year":"1993","journal-title":"J Biol Chem"},{"key":"2020021011132661600_awz328-B114","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","article-title":"Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models","volume":"7","author":"Moore","year":"2017","journal-title":"Mol Ther-Nucleic Acids"},{"key":"2020021011132661600_awz328-B115","doi-asserted-by":"crossref","first-page":"8938","DOI":"10.1093\/nar\/gkr608","article-title":"CAG repeats mimic CUG repeats in the misregulation of alternative splicing","volume":"39","author":"Mykowska","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B116","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1962210","article-title":"Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide","volume":"254","author":"Nielsen","year":"1991","journal-title":"Science (80-.)"},{"key":"2020021011132661600_awz328-B117","doi-asserted-by":"crossref","first-page":"eaap8677","DOI":"10.1126\/scitranslmed.aap8677","article-title":"Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7","volume":"10","author":"Niu","year":"2018","journal-title":"Sci Transl Med"},{"key":"2020021011132661600_awz328-B118","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0167-0115(95)00096-T","article-title":"Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain","volume":"59","author":"Ogawa","year":"1995","journal-title":"Regul Pept"},{"key":"2020021011132661600_awz328-B119","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1083\/jcb.201105092","article-title":"Cell biology of spinocerebellar ataxia","volume":"197","author":"Orr","year":"2012","journal-title":"J Cell Biol"},{"key":"2020021011132661600_awz328-B120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng0793-221","article-title":"Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1","volume":"4","author":"Orr","year":"1993","journal-title":"Nat Genet"},{"key":"2020021011132661600_awz328-B121","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant huntingtin in the CNS","volume":"41","author":"\u00d8stergaard","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B122","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonulceotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci Transl Med"},{"key":"2020021011132661600_awz328-B123","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/B978-0-444-51892-7.00027-9","article-title":"Machado-Joseph disease\/Spinocerebellar ataxia type 3","volume":"103","author":"Paulson","year":"2012","journal-title":"Handb Clin Neurol"},{"key":"2020021011132661600_awz328-B124","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrn.2017.92","article-title":"Polyglutamine spinocerebellar ataxias-from genes to potential treatments","volume":"18","author":"Paulson","year":"2017","journal-title":"Nat Rev Neurosci"},{"key":"2020021011132661600_awz328-B125","doi-asserted-by":"crossref","first-page":"9836","DOI":"10.1093\/nar\/gks710","article-title":"Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing","volume":"40","author":"Peacey","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(98)00185-5","article-title":"Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS","volume":"62","author":"Peng Ho","year":"1998","journal-title":"Mol Brain Res"},{"key":"2020021011132661600_awz328-B127","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/brain\/awp006","article-title":"Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin","volume":"132","author":"Pouladi","year":"2009","journal-title":"Brain"},{"key":"2020021011132661600_awz328-B128","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1212\/WNL.0000000000002777","article-title":"Degenerative ataxias, from genes to therapies","volume":"86","author":"Pulst","year":"2016","journal-title":"Neurology"},{"key":"2020021011132661600_awz328-B129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ng1196-269","article-title":"Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2","volume":"14","author":"Pulst","year":"1996","journal-title":"Nat Genet"},{"key":"2020021011132661600_awz328-B130","doi-asserted-by":"crossref","first-page":"10855","DOI":"10.1074\/jbc.M804813200","article-title":"Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells","volume":"284","author":"Ratovitski","year":"2009","journal-title":"J Biol Chem"},{"key":"2020021011132661600_awz328-B131","first-page":"717","article-title":"Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice","volume":"149","author":"Rifai","year":"1996","journal-title":"Am J Pathol"},{"key":"2020021011132661600_awz328-B132","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2020021011132661600_awz328-B133","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"2020021011132661600_awz328-B134","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol"},{"key":"2020021011132661600_awz328-B135","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1172\/JCI83185","article-title":"Targeting CAG repeat RNAs reduces Huntington \u2019 s disease phenotype independently of huntingtin levels find the latest version","volume":"126","author":"Ru\u00e9","year":"2016","journal-title":"J Clin Invest"},{"key":"2020021011132661600_awz328-B136","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2017.07.001","article-title":"Extracellular vesicles: novel promising delivery systems for therapy of brain diseases","volume":"262","author":"Rufino-Ramos","year":"2017","journal-title":"J Control Release"},{"key":"2020021011132661600_awz328-B137","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1093\/hmg\/ddv300","article-title":"Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy","volume":"24","author":"Sahashi","year":"2015","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B138","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","article-title":"Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders","volume":"421","author":"S\u00e1nchez","year":"2003","journal-title":"Nature"},{"key":"2020021011132661600_awz328-B139","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"2020021011132661600_awz328-B140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbpa.2018.05.018","article-title":"Therapeutic strategies for targeting neurodegenerative protein misfolding disorders","volume":"44","author":"Scannevin","year":"2018","journal-title":"Curr Opin Chem Biol"},{"key":"2020021011132661600_awz328-B141","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"2020021011132661600_awz328-B142","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1093\/nar\/27.24.4792","article-title":"Thermodynamic comparison of PNA\/DNA and DNA\/DNA hybridization reactions at ambient temperature","volume":"27","author":"Schwarz","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B143","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature22044","article-title":"Antisense oligonucleotide therapy for spinocerebellar ataxia type 2","volume":"544","author":"Scoles","year":"2017","journal-title":"Nature"},{"key":"2020021011132661600_awz328-B144","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-3-319-71779-1_8","article-title":"Spinocerebellar ataxia type 2","volume":"1049","author":"Scoles","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"2020021011132661600_awz328-B145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm801294h","article-title":"Short antisense oligonucleotides with novel 2\u2032-4\u2032 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals","volume":"52","author":"Seth","year":"2009","journal-title":"J Med Chem"},{"key":"2020021011132661600_awz328-B146","doi-asserted-by":"crossref","first-page":"13002","DOI":"10.1523\/JNEUROSCI.2789-11.2011","article-title":"Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia Type 3","volume":"31","author":"Shakkottai","year":"2011","journal-title":"J Neurosci"},{"key":"2020021011132661600_awz328-B147","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1093\/hmg\/ddu209","article-title":"Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease","volume":"23","author":"Sim\u00f5es","year":"2014","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B148","doi-asserted-by":"crossref","first-page":"e107434","DOI":"10.1371\/journal.pone.0107434","article-title":"Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients","volume":"9","author":"Skotte","year":"2014","journal-title":"PLoS One"},{"key":"2020021011132661600_awz328-B149","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J Clin Invest"},{"key":"2020021011132661600_awz328-B150","doi-asserted-by":"crossref","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","article-title":"Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease","volume":"10","author":"Southwell","year":"2018","journal-title":"Sci Transl Med"},{"key":"2020021011132661600_awz328-B151","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","article-title":"Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases","volume":"18","author":"Southwell","year":"2012","journal-title":"Trends Mol Med"},{"key":"2020021011132661600_awz328-B152","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol Ther"},{"key":"2020021011132661600_awz328-B153","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-130057","article-title":"Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of huntington\u2019s disease","volume":"2","author":"Stanek","year":"2013","journal-title":"J. Huntingtons. Dis"},{"key":"2020021011132661600_awz328-B154","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/nar\/16.8.3209","article-title":"Physicochemical properties of phosphorothioate oligodeoxynucleotides","volume":"16","author":"Stein","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-907X-3-1","article-title":"Inhibition of microRNA function by antimiR oligonucleotides","volume":"3","author":"Stenvang","year":"2012","journal-title":"Silence"},{"key":"2020021011132661600_awz328-B156","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc Natl Acad Sci"},{"key":"2020021011132661600_awz328-B157","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1093\/hmg\/ddu349","article-title":"Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity","volume":"23","author":"Sun","year":"2014","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B158","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B159","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington\u2019s disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med"},{"key":"2020021011132661600_awz328-B160","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/hmg\/ddm311","article-title":"Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic","volume":"17","author":"Takahashi","year":"2008","journal-title":"Hum Mol Genet"},{"key":"2020021011132661600_awz328-B161","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/ng0793-300","volume":"4","author":"Takiyama","year":"1993","journal-title":"Nat Genet"},{"key":"2020021011132661600_awz328-B162","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"key":"2020021011132661600_awz328-B163","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/intimm\/dxp030","article-title":"Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses","volume":"21","author":"Tluk","year":"2009","journal-title":"Int Immunol"},{"key":"2020021011132661600_awz328-B164","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","article-title":"Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 Mice","volume":"8","author":"Toonen","year":"2017","journal-title":"Mol Ther-Nucleic Acids"},{"key":"2020021011132661600_awz328-B165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep35200","article-title":"Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3","volume":"6","author":"Toonen","year":"2016","journal-title":"Sci Rep"},{"key":"2020021011132661600_awz328-B166","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/378403a0","article-title":"Polyglutamine expansion as a pathological epitope in Huntington\u2019s disease and four dominant cerebellar ataxias","volume":"378","author":"Trottier","year":"1995","journal-title":"Nature"},{"key":"2020021011132661600_awz328-B167","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1093\/nar\/gkv920","article-title":"The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA","volume":"43","author":"Vickers","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B168","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/nar\/29.6.1293","article-title":"Fully modified 2\u2032 MOE oligonucleotides redirect polyadenylation","volume":"29","author":"Vickers","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B169","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1073\/pnas.97.10.5633","article-title":"Potent and nontoxic antisense oligonucleotides containing locked nucleic acids","volume":"97","author":"Wahlestedt","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"2020021011132661600_awz328-B170","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1093\/nar\/gky145","article-title":"Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides","volume":"46","author":"Wang","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B182","first-page":"7314","article-title":"Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides","volume":"44","author":"Wang","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B171","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1093\/nar\/gku184","article-title":"Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides","volume":"42","author":"Ward","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2020021011132661600_awz328-B172","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/oli.2006.16.169","article-title":"Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302)","volume":"16","author":"Watanabe","year":"2006","journal-title":"Oligonucleotides"},{"key":"2020021011132661600_awz328-B173","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1021\/ar980051p","article-title":"Synthesis of 3\u2019-C- and 4\u2019-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA)","volume":"32","author":"Wengel","year":"1999","journal-title":"Acc Chem Res"},{"key":"2020021011132661600_awz328-B174","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1073\/pnas.90.10.4665","article-title":"Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system","volume":"90","author":"Whitesell","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020021011132661600_awz328-B175","doi-asserted-by":"crossref","first-page":"28270","DOI":"10.1074\/jbc.274.40.28270","article-title":"Properties of cloned and expressed human RNase H1","volume":"274","author":"Wu","year":"1999","journal-title":"J Biol Chem"},{"key":"2020021011132661600_awz328-B176","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J Biol Chem"},{"key":"2020021011132661600_awz328-B177","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nm1076","article-title":"RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia","volume":"10","author":"Xia","year":"2004","journal-title":"Nat Med"},{"key":"2020021011132661600_awz328-B178","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat Genet"},{"key":"2020021011132661600_awz328-B179","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2018.05.010","article-title":"Angubindin-1 opens the blood\u2013brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system","volume":"283","author":"Zeniya","year":"2018","journal-title":"J Control Release"},{"key":"2020021011132661600_awz328-B180","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1074\/jbc.R800041200","article-title":"Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1","volume":"284","author":"Zoghbi","year":"2009","journal-title":"J Biol Chem"},{"key":"2020021011132661600_awz328-B181","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol Rev"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/143\/2\/407\/32414033\/awz328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/143\/2\/407\/32414033\/awz328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T03:46:58Z","timestamp":1611719218000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/143\/2\/407\/5628274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,18]]},"references-count":184,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,11,18]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awz328","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,11,18]]}}}